Table 1 Baseline demographics, disease and clinical characteristics by line-of-treatment category
Demographic characteristics | N | First-line n = 118 | Second-line n = 996 | Overall n = 1114 |
|---|---|---|---|---|
Age, mean (SD) | 1113 | 59.1 (13.7) | 56.2 (12.4) | 56.5 (12.6) |
Female, n (%) | 1114 | 82 (69.5) | 822 (82.5) | 904 (81.1) |
Weight, mean (SD) | 1102 | 75.5 (15.9) | 74.5 (17.0) | 74.6 (16.9) |
Disease characteristics | ||||
Mean disease duration, years (SD) | 1079 | 6.9 (7.7) | 11.5 (8.9) | 11.0 (8.9) |
Disease duration, n (%) | ||||
≤2 years | 41 (35.3) | 100 (10.4) | 141 (13.1) | |
3–5 years | 30 (25.9) | 200 (20.8) | 230 (21.3) | |
6–10 years | 21 (18.1) | 242 (25.1) | 263 (24.4) | |
>10 years | 24 (20.7) | 421 (43.7) | 445 (41.2) | |
Previous treatments | ||||
Previously treated with biologic agents, n (%) | 1114 | 0 (0.0) | 996 (100) | 996 (89.4) |
At least one anti-TNF agent, n (%) | 0 (0.0) | 978 (98.2) | 978 (87.8) | |
Anti-TNF only | 0 (0.0) | 790 (79.3) | 790 (70.9) | |
Anti-TNF and another biologic | 0 (0.0) | 188 (18.9) | 188 (16.9) | |
Other mechanisms of action only | 0 (0.0) | 18 (1.8) | 18 (1.6) | |
Number of prior anti-TNF agents, mean (SD) | 0 (0.0) | 1.6 (0.7) | 1.4 (0.8) | |
One, n (%) | 0 (0.0) | 480 (48.2) | 480 (43.1) | |
Two, n (%) | 0 (0.0) | 405 (40.7) | 405 (36.4) | |
Three, n (%) | 0 (0.0) | 93 (9.3) | 93 (8.3) | |
Clinical characteristics | N* | First-line N = 111 | Second-line N = 968 | Overall N = 1079 |
Tender joint count (28), mean (SD) | 1052 | 11.5 (7.3) | 11.4 (7.3) | 11.4 (7.3) |
Swollen joint count (28), mean (SD) | 1069 | 9.5 (5.8) | 7.8 (5.8) | 8.0 (5.9) |
Patient global assessment, mean (SD) (VAS 100 mm) | 1002 | 61.9 (22.1) | 66.2 (20.1) | 65.8 (20.3) |
Physician global assessment, mean (SD) (VAS 100 mm) | 937 | 61.9 (18.7) | 61.8 (19.4) | 61.8 (19.3) |
Patient global assessment of pain, mean (SD) (VAS 100 mm) | 990 | 59.9 (24.5) | 65.9 (20.7) | 65.3 (21.1) |
Patients with erosions, n (%) | 926 | 58 (58.0) | 590 (71.4) | 648 (70.0) |
DAS28 (ESR), mean (SD) | 748 | 5.5 (1.3) | 5.6 (1.2) | 5.6 (1.2) |
DAS28 (CRP), mean (SD) | 216 | 4.8 (1.1) | 5.2 (1.3) | 5.2 (1.3) |
CDAI, mean (SD) | 919 | 33.4 (13.1) | 31.5 (13.0) | 31.7 (13.0) |
SDAI, mean (SD) | 824 | 35.4 (13.8) | 33.9 (13.8) | 34.0 (13.8) |
HAQ-DI, mean (SD) | 988 | 1.42 (0.59) | 1.56 (0.67) | 1.55 (0.67) |
CRP mg/L, mean (SD) | 943 | 19.6 (32.5) | 24.4 (40.6) | 23.9 (39.9) |
ESR mm/hour, mean (SD) | 988 | 32.5 (23.6) | 35.5 (24.5) | 35.2 (24.4) |
Rheumatoid factor positive, n (%) | 886 | 64 (68.1) | 549 (69.3) | 613 (69.2) |
Anti-CCP positive, n (%) | 598 | 36 (59.0) | 354 (65.9) | 390 (65.2) |